The administration of selective estrogen receptor modulators (SERMs) for a period of one to four weeks has been shown to induce a significant antiproliferative effect in estrogen receptor (ER)-positive breast cancers [1,2]. This evidence concerns the gene ESR1 and breast carcinoma.